Warning! GuruFocus detected
3 Severe warning signs
with IRD.
Try a 7-Day Free Trial
to check it out.
What is a stock summary page? Click here for an overview.
Business Description
Opus Genetics Inc
NAICS : 325412
SIC : 2834
ISIN : US67577R1023
Share Class Description:
IRD: Ordinary SharesDescription
Opus Genetics Inc is a clinical-stage ophthalmic biopharmaceutical company developing therapies to treat patients with inherited retinal diseases (IRDs) and therapies to treat patients with other retinal and refractive disorders. The pipeline includes adeno-associated virus (AAV)-based gene therapies that address mutations in genes that cause different forms of bestrophinopathy, Leber congenital amaurosis (LCA) and retinitis pigmentosa. The pipeline also includes Phentolamine Ophthalmic Solution 0.75%, a non-selective alpha-1 and alpha-2 adrenergic antagonist to reduce pupil size, and APX3330, a novel small-molecule inhibitor of Ref-1 to slow the progression of non-proliferative diabetic retinopathy.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | 0.85 | |||||
| Piotroski F-Score | 2/9 | |||||
| Altman Z-Score | -1.38 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | 50.5 | |||||
| 3-Year EPS without NRI Growth Rate | 49 | |||||
| 3-Year FCF Growth Rate | 67.1 | |||||
| Future 3-5Y Total Revenue Growth Rate Estimate | 74.55 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.43 | |||||
| 9-Day RSI | 59.79 | |||||
| 14-Day RSI | 57.03 | |||||
| 3-1 Month Momentum % | 3.85 | |||||
| 6-1 Month Momentum % | -21.17 | |||||
| 12-1 Month Momentum % | -46.8 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 6.63 | |||||
| Quick Ratio | 6.63 | |||||
| Cash Ratio | 6.02 | |||||
| Days Sales Outstanding | 141.08 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -30.1 | |||||
| Shareholder Yield % | -13.21 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Operating Margin % | -351.68 | |||||
| Net Margin % | -324.45 | |||||
| FCF Margin % | -162.15 | |||||
| ROE % | -61.47 | |||||
| ROA % | -55.45 | |||||
| ROIC % | -1672.64 | |||||
| 3-Year ROIIC % | -1849.46 | |||||
| ROC (Joel Greenblatt) % | -884.33 | |||||
| ROCE % | -67.11 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Forward PE Ratio | 7.48 | |||||
| PS Ratio | 3.21 | |||||
| PB Ratio | 0.82 | |||||
| Price-to-Tangible-Book | 0.82 | |||||
| EV-to-EBIT | 0.01 | |||||
| EV-to-Forward-EBIT | -2.42 | |||||
| EV-to-EBITDA | 0.01 | |||||
| EV-to-Forward-EBITDA | 0.01 | |||||
| EV-to-Revenue | -0.04 | |||||
| EV-to-Forward-Revenue | 0.13 | |||||
| EV-to-FCF | 0.02 | |||||
| Price-to-GF-Value | 1.39 | |||||
| Price-to-Net-Current-Asset-Value | 0.82 | |||||
| Price-to-Net-Cash | 0.91 | |||||
| Earnings Yield (Greenblatt) % | No Debt | |||||
| FCF Yield % | -40.24 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:IRD
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Opus Genetics Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 8.381 | ||
| EPS (TTM) ($) | -1.09 | ||
| Beta | 0.95 | ||
| 3-Year Sharpe Ratio | -0.48 | ||
| 3-Year Sortino Ratio | -0.65 | ||
| Volatility % | 59.29 | ||
| 14-Day RSI | 57.03 | ||
| 14-Day ATR ($) | 0.09949 | ||
| 20-Day SMA ($) | 1.029965 | ||
| 12-1 Month Momentum % | -46.8 | ||
| 52-Week Range ($) | 0.81 - 2.34 | ||
| Shares Outstanding (Mil) | 31.57 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Opus Genetics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Opus Genetics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Opus Genetics Inc Frequently Asked Questions
What is Opus Genetics Inc(IRD)'s stock price today?
The current price of IRD is $1.07. The 52 week high of IRD is $2.34 and 52 week low is $0.81.
When is next earnings date of Opus Genetics Inc(IRD)?
The next earnings date of Opus Genetics Inc(IRD) is 2025-03-26 Est..
Does Opus Genetics Inc(IRD) pay dividends? If so, how much?
Opus Genetics Inc(IRD) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers